Merck and Blackstone Partner in $700 Million Deal to Advance TROP2-Targeting Cancer Therapy

Merck has entered into a $700 million agreement with Blackstone Life Sciences to support the development of an antibody-drug conjugate (ADC) targeting TROP2, a protein commonly associated with various cancers. The therapy, which is part of Merck’s partnership with Sichuan Kelun Pharmaceutical Co., Ltd., is currently undergoing 15 Phase III clinical trials. This collaboration highlights the growing trend of risk-sharing deals in the pharmaceutical industry, where financial firms like Blackstone provide funding to accelerate drug development.

The ADC therapy aims to target TROP2, a protein linked to tumor growth and progression in multiple cancer types. Merck’s partnership with Sichuan Kelun focuses on advancing this treatment through late-stage clinical trials. The $700 million investment from Blackstone Life Sciences will help fund these trials and further research efforts. Risk-sharing agreements such as this allow pharmaceutical companies to mitigate financial risks while pursuing innovative therapies for complex diseases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 4, 2025

Related posts:

Novel Method Combines Heart Biopsy and Device Implantation to Reduce Risk of Complications Paysign Reports Millions Saved Through Data-Driven Analysis of First-Fill Prescriptions to Address Copay Maximizer Challenges DryEye Rescue Launches Rescue Link Platform for Eye Care Providers to Send OTC Recommendations via Text Study Reveals Impact of Nonuniform Cooling on Polymer Strength in Fused Filament Fabrication

Author

GOAI